Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VIRX | US
0.01
3.14%
Healthcare
Biotechnology
30/06/2024
18/10/2024
0.23
0.22
0.23
0.22
Viracta Therapeutics Inc. a clinical-stage precision oncology company focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val an all-oral combination therapy of its proprietary investigational drug nanatinostat and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials including NAVAL-1 an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510 a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals Inc. and changed its name to Viracta Therapeutics Inc. in February 2021. Viracta Therapeutics Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea California.
View LessLow Market Beta (-0.4 to 0.8)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
29.9%1 month
29.7%3 months
80.2%6 months
87.5%-
-
3.41
7.05
0.60
-0.48
-
-
-49.04M
-
-
-
-
-
-
-208.67
4.87
4.28
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.04
Range3M
0.38
Rel. volume
0.91
Price X volume
37.46K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd | URGN | Biotechnology | 12.73 | 0 | -0.86% | n/a | 326.69% |
Unicycive Therapeutics Inc. Common Stock | UNCY | Biotechnology | 0.429 | 0 | -5.69% | n/a | -315.38% |
Unity Biotechnology Inc | UBX | Biotechnology | 1.4 | 0 | 1.45% | n/a | 109.64% |
SABSW | SABSW | Biotechnology | 0.0492 | 0 | 4.02% | 0.17 | 11.58% |
Revolution Medicines Inc. Warrant | RVMDW | Biotechnology | 0.101 | 0 | 0.00% | n/a | 5.40% |
REVBW | REVBW | Biotechnology | 0.0133 | 0 | -0.75% | n/a | 0.00% |
Rocket Pharmaceuticals Inc. Warrant | RCKTW | Biotechnology | 0.0709 | 0 | 14.35% | n/a | 0.00% |
OCEAW | OCEAW | Biotechnology | 0.0388 | 0 | -3.00% | n/a | -16.02% |
Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.05 | 0 | -14.63% | n/a | 1.72% |
NKGen Biotech Inc. Warrants | NKGNW | Biotechnology | 0.0248 | 0 | -58.67% | n/a | -40.33% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | 9.09 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.48 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 3.41 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 80.21 | 72.80 | Par |
Debt to Equity | 7.05 | -1.23 | Expensive |
Debt to Assets | 0.60 | 0.25 | Expensive |
Market Cap | - | 3.66B | - |